Archives — Current Month (2)
An H.C. Wainwright & Co. report reviewed this firm's latest news concerning a data readout, trial approval and therapeutic application.
This company takes a step forward in its efforts to protect its intellectual property.
|"DRRX's Q3/18 revenue benefited from a $5M milestone from Indivior."|
|"PMN is looking to outlicense PMN310 after the Phase 1 study."|